Revumenib

• Description:

  Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell based IC50 of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) [1].

• Product Name Alternative:

  SNDX-5613

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319

• Target:

  Epigenetic Reader Domain

• Type:

  Reference compound

• Related Pathways:

  Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/revumenib.html

• Purity:

  99.99

• Solubility:

  DMSO : ≥ 25 mg/mL

• Smiles:

  O=C(N(CC)C(C)C)C1=CC(F)=CC=C1OC2=CN=CN=C2N3CC4(CCN(C[C@H]5CC[C@H](NS(=O)(CC)=O)CC5)CC4)C3

• Molecular Formula:

  C32H47FN6O4S

• Molecular Weight:

  630.82

• Precautions:

  H302, H315, H319

• References & Citations:

  [1]A drug, SNDX-5613, to treat acute leukemia with a KMT2A translocation or an NPM1 mutation that has come back (relapsed) or has not gotten better with treatment (refractory) .

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• CAS Number:

  [2169919-21-3]